Zai Lab Ltd
ZLABHealthcare|Biotechnology|China
$20.49
+0.52 (+2.60%)
Tangible Book
$5.25
Clinical Trials (44)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07211776 A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease | Thyroid Eye Disease (TED) | P3 | Recruiting | 99 | RCT, Double-blind | ZL-1109 (VRDN-003), Placebo |
| NCT07218146 A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Small-cell Lung Cancer | P3 | Recruiting | 480 | RCT, Open-label | ZL-1310, Investigator's Choice of Therapy |
| NCT07204275 Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Primary Membranous Nephropathy | P2P3 | Recruiting | 176 | RCT, Double-blind | Povetacicept, Tacrolimus |
| NCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | Carcinoma, Non-Small-Cell Lung | P3 | Active | 190 | RCT, Open-label | Repotrectinib, Crizotinib |
| NCT06380907 A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis | Plaque Psoriasis | P2 | Recruiting | 250 | RCT, Double-blind | ZL-1102 1% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel QD for 16 weeks, Placebo ZL-1102 0% w/w gel BID for 16 weeks, Placebo ZL-1102 0% w/w gel QD for 16 weeks |
| NCT06885281 A Study of ZL-1310 in Participants With Selected Solid Tumors | Solid Tumors | P1P2 | Recruiting | 166 | Open-label | ZL-1310 |
| NCT04716686 Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | Endometrial Carcinoma, Serous Carcinoma | P2 | Recruiting | 83 | Open-label | Niraparib |
| NCT03093116 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Locally Advanced Solid Tumors, Metastatic Solid Tumors | P1P2 | Recruiting | 500 | Open-label | Oral repotrectinib (TPX-0005) |
| NCT07235384 A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis (AD) | P1 | Recruiting | 84 | RCT, Double-blind | ZL-1503, Placebo, ZL-1503, Placebo |
| NCT07374848 Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | Solid Tumors, Sarcomas | P1 | Recruiting | 180 | Open-label | ZL-6201 |
| NCT06179069 A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | SCLC | P1 | Recruiting | 339 | Open-label | ZL-1310, Atezolizumab, Carboplatin |
| NCT05919823 A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Schizophrenia | P3 | Completed | 202 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT03516084 A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer | P3 | Terminated | 185 | RCT, Double-blind | ZL-2306(nirapairb), Placebo |
| NCT06162286 A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP | Community-acquired Bacterial Pneumonia | P3 | Unknown | 100 | RCT, Double-blind | Omadacycline, Moxifloxacin |
| NCT03705156 Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient | Platinum-sensitive Relapsed Ovarian Cancer | P3 | Unknown | 265 | RCT, Double-blind | ZL-2306(nirapairb), Placebos |
| NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | Gastric Cancer, Gastroesophageal Junction Cancer | P2P3 | Completed | 82 | RCT, Open-label | margetuximab, Retifanlimab, Tebotelimab, Trastuzumab |
| NCT03709316 A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | Ovarian Cancer | P3 | Unknown | 384 | RCT, Double-blind | ZL-2306 (Nirapairb), Placebo Comparator |
| NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P3 | Completed | 547 | RCT, Double-blind | Bemarituzumab, mFOLFOX6, Placebo |
| NCT03516071 A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | Hepatocellular Carcinoma (HCC) | P2 | Completed | 90 | RCT, Open-label | Brivanib 800 mg, QD, Brivanib 400 mg, BID |
| NCT04633122 A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | Gastrointestinal Stromal Tumor(GIST) | P2 | Completed | 108 | RCT, Open-label | Ripretinib, Sunitinib |
| NCT04392102 A Study of Niraparib in Patients With Relapsed Ovarian Cancer | Ovarian Cancer | P2 | Completed | 15 | Open-label | ZL-2306(Niraparib） |
| NCT05810961 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) | Membranous Nephropathy | P2 | Terminated | 8 | RCT, Double-blind | efgartigimod IV |
| NCT03694522 A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer | Gastric Cancer | P2 | Completed | 155 | RCT, Double-blind | Bemarituzumab, Placebo, Modified FOLFOX6 |
| NCT05130515 Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. | Platinum-resistant Recurrent Clear Cell Ovarian Cancer | P2 | Completed | 6 | Open-label | Niraparib, Anlotinib |
| NCT03134352 Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema | Eczema | P2 | Completed | 290 | RCT, Double-blind | ZL-3101, Placebo |
| NCT04262804 A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | Breast Cancer Metastatic | P2 | Unknown | 123 | RCT, Open-label | Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine ) |
| NCT04212221 MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | Advanced Hepatocellular Carcinoma (HCC) | P1P2 | Terminated | 89 | Open-label | MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate |
| NCT04282980 A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | Gastrointestinal Stromal Tumors | P2 | Completed | 39 | Open-label | DCC-2618 |
| NCT05810948 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | Lupus Nephritis | P2 | Completed | 73 | RCT, Double-blind | efgartigimod IV |
| NCT05385068 A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi | Epithelial Ovarian Cancer | P2 | Unknown | 35 | Open-label | Niraparib |
| NCT04217798 Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer | Ovarian Cancer | P2 | Unknown | 36 | Open-label | Niraparib |
| NCT02397005 Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects | Chronic Obstructive Pulmonary Disease, Asthma | P1 | Unknown | 120 | RCT, Double-blind | ZL-2102, Placebo matching ZL-2102 |
| NCT05859464 A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | Malignant Solid Tumor | P1 | Terminated | 34 | Open-label | ZL-1218, Pembrolizumab |
| NCT06462326 A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers | Healthy Volunteer | P1 | Completed | 24 | RCT, Double-blind | Moxifloxacin Oral Tablet, Omadacycline Oral Tablet |
| NCT05866354 To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies | Solid Malignancies | P1 | Completed | 19 | Open-label | Tisotumab Vedotin |
| NCT04398108 A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC | HER2 Positive Metastatic Breast Cancer | P1 | Completed | 16 | Open-label | Margetuximab Margetuximab-IV |
| NCT07658482 A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers | Healthy Volunteers | P1 | Not Yet Recruiting | 36 | RCT, Open-label | ZL-1503, ZL-1503, ZL-1503 |
| NCT05065710 A Study of ZL-1211 in Patients With Advanced Solid Tumor | Advanced Solid Tumor | P1 | Completed | 34 | Open-label | ZL-1211 |
| NCT05263986 The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors | Advanced or Metastatic Solid Tumor | P1 | Unknown | 22 | Open-label | MRTX849 |
| NCT03551171 The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | Ovarian Cancer | P1 | Completed | 42 | Open-label | ZL-2306 (niraparib) |
| NCT04653038 A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma | Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma | P1 | Terminated | 92 | Open-label | MGD013 |
| NCT04257617 A Trial of ZL-1201 in Subjects With Advanced Cancer | Advanced Cancer | P1 | Completed | 37 | Open-label | ZL-1201 |
| NCT04178460 A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | Gastric Cancer, Triple Negative Breast Cancer | P1 | Terminated | 60 | Open-label | Niraparib combined with MGD013 |
| NCT04281576 Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | Gastric Cancer, GastroEsophageal Cancer | N/A | Completed | 28 | Open-label | Oxaliplatin, Capecitabine, Trastuzumab |